Display options
Cite
Brulhart-Meynet MC, Thomas A, Sidibé J, et al. Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment. Physiol Rep. 2021;9(6):e14786doi: 10.14814/phy2.14786.
Brulhart-Meynet, M. C., Thomas, A., Sidibé, J., Visentin, F., Dusaulcy, R., Schwitzgebel, V., Pataky, Z., Philippe, J., Vuilleumier, N., James, R. W., Gosmain, Y., & Frias, M. A. (2021). Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment. Physiological reports, 9(6), e14786. https://doi.org/10.14814/phy2.14786
Brulhart-Meynet, Marie-Claude, et al. "Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment." Physiological reports vol. 9,6 (2021): e14786. doi: https://doi.org/10.14814/phy2.14786
Brulhart-Meynet MC, Thomas A, Sidibé J, Visentin F, Dusaulcy R, Schwitzgebel V, Pataky Z, Philippe J, Vuilleumier N, James RW, Gosmain Y, Frias MA. Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment. Physiol Rep. 2021 Mar;9(6):e14786. doi: 10.14814/phy2.14786. PMID: 33769715; PMCID: PMC7995544.
Copy Download .nbib Format: NLM
Share it on

Physiol Rep. 2021 Mar;9(6):e14786. doi: 10.14814/phy2.14786.

Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment.

Physiological reports

Marie-Claude Brulhart-Meynet, Aurélien Thomas, Jonathan Sidibé, Florian Visentin, Rodolphe Dusaulcy, Valérie Schwitzgebel, Zoltan Pataky, Jacques Philippe, Nicolas Vuilleumier, Richard W James, Yvan Gosmain, Miguel A Frias

Affiliations

  1. Division of Endocrinology, Diabetes, Nutrition and Patient Education, Department of Medicine, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland.
  2. Unit of Toxicology, University Centre of Legal Medicine, Lausanne-Geneva, Switzerland.
  3. Pediatric Endocrine and Diabetes Unit, Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.
  4. Division of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
  5. Department of Medicine, Medical Faculty, Geneva University, Geneva, Switzerland.

PMID: 33769715 PMCID: PMC7995544 DOI: 10.14814/phy2.14786

Abstract

Beta cell failure is one of the most important features of type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) has been proposed to improve β-cell function. However, the mechanisms involved in this process are still poorly understood. The aim of this study was to investigate the contribution of sphingosine-1-phosphate (S1P) in the impact of HDL treatment on insulin secretion by pancreatic β-cells and to determine its mechanisms. Primary cultures of β-cells isolated from rat were treated with or without HDL in the presence or absence of S1P pathway inhibitors and insulin secretion response was analyzed. The S1P content of HDL (HDL-S1P) isolated from T2DM patients was analyzed and correlated to the HDL-induced insulin secretion. The expression of genes involved in the biosynthesis of the insulin was also evaluated. HDL as well as S1P treatment enhanced glucose-stimulated insulin secretion (GSIS). In HDL isolated from T2DM patients, while HDL-S1P was strongly correlated to its pro-secretory capacity (r = 0.633, p = 0.005), HDL-cholesterol and apolipoprotein AI levels were not. HDL-induced GSIS was blocked by the S1P1/3 antagonist but not by the S1P2 antagonist, and was also accompanied by increased intracellular S1P in β-cells. We also observed that HDL improved GSIS without significant changes in expression levels of insulin biosynthesis genes. Our present study highlights the importance HDL-S1P in GSIS in T2DM patients and demonstrates that HDL induces insulin secretion by a process involving both intra- and extra-cellular sources of S1P independently of an effect on insulin biosynthesis genes.

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Keywords: glucose-stimulated insulin secretion; high-density lipoproteins; primary pancreatic beta cells; sphingosine-1-phosphate; type 2 diabetes mellitus

References

  1. Int J Mol Med. 2017 Feb;39(2):243-252 - PubMed
  2. J Am Coll Cardiol. 2008 Jun 10;51(23):2199-211 - PubMed
  3. Diabetes. 2012 May;61(5):1100-11 - PubMed
  4. Endocrinology. 2009 Oct;150(10):4521-30 - PubMed
  5. J Biol Chem. 2010 Oct 22;285(43):33381-33393 - PubMed
  6. Cardiovasc Res. 2009 May 1;82(2):201-11 - PubMed
  7. Diabetes. 2016 Jul;65(7):1838-48 - PubMed
  8. J Biol Chem. 2012 Apr 13;287(16):13457-64 - PubMed
  9. Circulation. 2009 Apr 21;119(15):2103-11 - PubMed
  10. Mol Endocrinol. 2012 Apr;26(4):696-709 - PubMed
  11. J Biol Chem. 2017 Dec 8;292(49):20292-20304 - PubMed
  12. J Am Coll Cardiol. 2015 Sep 29;66(13):1470-85 - PubMed
  13. Pharmacol Rev. 2006 Sep;58(3):342-74 - PubMed
  14. Mol Endocrinol. 2009 Oct;23(10):1572-86 - PubMed
  15. J Clin Invest. 2011 Jul;121(7):2693-708 - PubMed
  16. Curr Opin Lipidol. 2016 Feb;27(1):8-13 - PubMed
  17. J Biol Chem. 2003 May 16;278(20):18368-75 - PubMed
  18. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2261-7 - PubMed
  19. Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1642-8 - PubMed
  20. Arterioscler Thromb Vasc Biol. 2016 May;36(5):817-24 - PubMed
  21. Eur J Clin Invest. 2018 Feb;48(2): - PubMed
  22. J Lipid Res. 2017 Feb;58(2):325-338 - PubMed
  23. Biochem J. 2000 Dec 15;352 Pt 3:809-15 - PubMed
  24. FASEB J. 2015 Aug;29(8):3357-69 - PubMed
  25. Endocr J. 2000 Jun;47(3):261-9 - PubMed
  26. Front Pharmacol. 2015 Oct 31;6:258 - PubMed
  27. Curr Cardiol Rep. 2007 Nov;9(6):493-8 - PubMed
  28. Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S27-31 - PubMed
  29. Cell Calcium. 2012 Mar-Apr;51(3-4):300-8 - PubMed
  30. Front Pharmacol. 2015 Oct 20;6:243 - PubMed

Publication Types